Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX.
Liao MZ, Deng R, Gibiansky L, Lu T, Agarwal P, Dere R, Lee C, Hirata J, Herbaux C, Salles G, Li C, Miles D. Liao MZ, et al. Among authors: gibiansky l. Clin Transl Sci. 2023 Dec;16(12):2744-2755. doi: 10.1111/cts.13669. Epub 2023 Oct 31. Clin Transl Sci. 2023. PMID: 37864313 Free PMC article.
Integrated Two-Analyte Population Pharmacokinetic Model for Antibody-Drug Conjugates in Patients: Implications for Reducing Pharmacokinetic Sampling.
Lu D, Gibiansky L, Agarwal P, Dere RC, Li C, Chu YW, Hirata J, Joshi A, Jin JY, Girish S. Lu D, et al. Among authors: gibiansky l. CPT Pharmacometrics Syst Pharmacol. 2016 Dec;5(12):665-673. doi: 10.1002/psp4.12137. Epub 2016 Nov 10. CPT Pharmacometrics Syst Pharmacol. 2016. PMID: 27863168 Free PMC article. Clinical Trial.
Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Kågedal M, Gibiansky L, Xu J, Wang X, Samineni D, Chen SC, Lu D, Agarwal P, Wang B, Saad O, Koppada N, Fine BM, Jin JY, Girish S, Li C. Kågedal M, et al. Among authors: gibiansky l. J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):537-548. doi: 10.1007/s10928-017-9544-y. Epub 2017 Sep 16. J Pharmacokinet Pharmacodyn. 2017. PMID: 28918591
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
Deng R, Gibiansky L, Lu T, Agarwal P, Ding H, Li X, Kshirsagar S, Lu D, Li C, Girish S, Wang J, Boyer M, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D. Deng R, et al. Among authors: gibiansky l. Clin Pharmacokinet. 2019 Dec;58(12):1621-1634. doi: 10.1007/s40262-019-00788-8. Clin Pharmacokinet. 2019. PMID: 31209657 Clinical Trial.
Exposure-response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study.
Deng R, Gibiansky L, Lu T, Li X, Lu D, Li C, Girish S, Wang J, Boyer M, Shankar N, Humphrey K, Freise KJ, Salem AH, Seymour JF, Kater AP, Miles D. Deng R, et al. Among authors: gibiansky l. Leuk Lymphoma. 2020 Jan;61(1):56-65. doi: 10.1080/10428194.2019.1657575. Epub 2019 Sep 24. Leuk Lymphoma. 2020. PMID: 31549889 Clinical Trial.
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Shi R, Lu T, Ku G, Ding H, Saito T, Gibiansky L, Agarwal P, Li X, Jin JY, Girish S, Miles D, Li C, Lu D. Shi R, et al. Among authors: gibiansky l. Cancer Chemother Pharmacol. 2020 Sep;86(3):347-359. doi: 10.1007/s00280-020-04119-8. Epub 2020 Aug 8. Cancer Chemother Pharmacol. 2020. PMID: 32770353 Free PMC article. Clinical Trial.
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Lu D, Lu T, Shi R, Gibiansky L, Agarwal P, Shemesh CS, Dere RC, Ogbu U, Hirata J, Chanu P, Girish S, Jin JY, Li C, Miles D. Lu D, et al. Among authors: gibiansky l. Pharm Res. 2020 Dec 1;37(12):252. doi: 10.1007/s11095-020-02933-6. Pharm Res. 2020. PMID: 33258982 Free PMC article.
Population Pharmacokinetics and Exposure-Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
Samineni D, Huang W, Gibiansky L, Ding H, Zhang R, Li C, Sinha A, Rajwanshi R, Humphrey K, Bazeos A, Salem AH, Miles D. Samineni D, et al. Among authors: gibiansky l. Adv Ther. 2022 Jan;39(1):598-618. doi: 10.1007/s12325-021-01919-z. Epub 2021 Nov 25. Adv Ther. 2022. PMID: 34822104 Free PMC article. Clinical Trial.
63 results